STEREOTACTIC BODY RADIOTHERAPY FOR TREATMENT OF ADRENAL METASTASES

被引:116
作者
Chawla, Sheema [1 ]
Chen, Yuhchyau [1 ]
Katz, Alan W. [1 ]
Muhs, Ann G. [1 ]
Philip, Abraham [1 ]
Okunieff, Paul [1 ]
Milano, Michael T. [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2009年 / 75卷 / 01期
关键词
Adrenal metastases; Stereotactic body radiotherapy; RADIATION-THERAPY SBRT; LUNG-CANCER; TUMORS; OLIGOMETASTASES; CARCINOMA;
D O I
10.1016/j.ijrobp.2008.10.079
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the dosimetry and outcomes of patients undergoing stereotactic body radiotherapy (SBRT) for metastases to the adrenal glands. Methods and Materials: At the University of Rochester, patients have been undergoing SBRT for limited metastases since 2001. We retrospectively reviewed 30 patients who had undergone SBRT for adrenal metastases from various primary sites, including lung (n = 20), liver (n = 3), breast (n = 3), melanoma (n = 1), pancreas (n = 1), head and neck (n = 1), and unknown primary (n = 1). Results: Of the 30 patients, 14 with five or fewer metastatic lesions (including adrenal) underwent SBRT, with the intent of controlling all known sites of metastatic disease, and 16 underwent SBRT for palliation or prophylactic palliation of bulky adrenal metastases. The prescribed dose ranged from 16 Gy in 4 fractions to 50 Gy in 10 fractions. The median dose was 40 Gy. Of the 30 patients, 24 had >3 months of follow-up with serial computed tomography. Of these 24 patients, 1 achieved a complete response, 15 achieved a partial response, 4 had stable disease, and 4 developed progressive disease. No patient developed symptomatic progression of their adrenal metastases. The 1-year survival, local control, and distant control rate was 44%, 55%, and 13%, respectively. No patient developed Radiation Therapy Oncology Group Grade 2 or greater toxicity. Conclusion: SBRT for adrenal metastases is well tolerated. Most patients developed widespread metastases shortly after treatment. Local control was poor, although this was a patient population selected for adverse risk factors, such as bulky disease. Additional studies are needed to determine the efficacy of SBRT for oligometastatic adrenal metastases, given the propensity of these patients to develop further disease progression. (C) 2009 Elsevier Inc.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 24 条
  • [1] Isolated adrenal mass in patients with a history of cancer: Remember pheochromocytoma
    Adler, Joel T.
    Mack, Eberhard
    Chen, Herbert
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (08) : 2358 - 2362
  • [2] Hsieh Meng-Hsuan, 2005, Kaohsiung Journal of Medical Sciences, V21, P371
  • [3] Real-time tumor-tracking radiotherapy for adrenal tumors
    Katoh, Norio
    Onimaru, Rikiya
    Sakuhara, Yusuke
    Abo, Daisuke
    Shimizu, Shinichi
    Taguchi, Hiroshi
    Watanabe, Yoshiaki
    Shinohara, Nobuo
    Ishikawa, Masayori
    Shirato, Hiroki
    [J]. RADIOTHERAPY AND ONCOLOGY, 2008, 87 (03) : 418 - 424
  • [4] Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases
    Katz, Alan W.
    Carey-Sampson, Madeleine
    Muhs, Ann G.
    Milano, Michael T.
    Schell, Michael C.
    Okunieff, Paul
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (03): : 793 - 798
  • [5] Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases
    Kavanagh, BD
    McGarry, RC
    Timmerman, RD
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2006, 16 (02) : 77 - 84
  • [6] Kim SH, 1998, CANCER, V82, P389
  • [7] Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital
    Lam, KY
    Lo, CY
    [J]. CLINICAL ENDOCRINOLOGY, 2002, 56 (01) : 95 - 101
  • [8] A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions
    Milano, Michael T.
    Katz, Alan W.
    Muhs, Ann G.
    Philip, Abraham
    Buchholz, Daniel J.
    Schell, Michael C.
    Okunieff, Paul
    [J]. CANCER, 2008, 112 (03) : 650 - 658
  • [9] MILANO MT, 2008, INT J RADIAT ONCOL, V70, P1057
  • [10] Miyaji N, 1999, Radiat Med, V17, P71